Suchergebnisse - "Merz, Valeria"

PubPharm (44)

21

Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients

enthalten in: Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al. | 2021

von Melisi, D. | Cavaliere, A. | Gobbo, S. | +18

22

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

enthalten in: Journal for immunotherapy of cancer | 2021

von Melisi, D. | Oh, D. | Hollebecque, A. | +16

23

Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma

enthalten in: Future oncology (London, England) | 2021

von Merz, V. | Zecchetto, C. | Melisi, D.

24

Targeting KRAS : The Elephant in the Room of Epithelial Cancers

enthalten in: Frontiers in oncology | 2021

von Merz, V. | Gaule, M. | Zecchetto, C. | +10

25

Electronic Medical Record-Assisted Telephone Follow-Up of Breast Cancer Survivors During the COVID-19 Pandemic : A Single Institution Experience

enthalten in: JCO oncology practice | 2021

von Merz, V. | Ferro, A. | Piras, E. | +3

26

Efficacy and safety of PD1/PDL1 blockade with platinum‐based chemotherapy for extensive small cell lung cancer : A pooled analysis of randomized trials

enthalten in: European Journal of Clinical Investigation | 2021

von Messina, C. | Salati, M. | Messina, M. | +3

27

Impact of COVID-19 outbreak on cancer immunotherapy in Italy : a survey of young oncologists

enthalten in: Journal for immunotherapy of cancer | 2020

von Ottaviano, M. | Curvietto, M. | Rescigno, P. | +93

28

Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2020

von Merz, V. | Zecchetto, C. | Santoro, R. | +11

29

Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients

enthalten in: Cancers | 2020

von Merz, V. | Cavaliere, A. | Messina, C. | +6

30

Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer

enthalten in: Molecular cancer therapeutics | 2020

von Santoro, R. | Zanotto, M. | Simionato, F. | +8